Commentary
dMMR Status Eliminates "Gray Area" in Adjuvant Treatment for Stage II Colon Cancer
Axel Grothey: dMMR Status Eliminates "Gray Area" in Adjuvant Treatment for Stage II Colon Cancer
dMMR Status Eliminates "Gray Area" in Adjuvant Treatment for Stage II Colon Cancer
Dr. Axel Grothey is Professor of Oncology and Consultant, Medical Oncology, Mayo Clinic, Rochester, Minnesota. View profile. 1. In your view, which development in colon cancer that has occurred in 2009 could have the most significant impact on oncology?One area that emerged very prominently this year relates to the use of adjuvant therapy in colon cancer. After 2 phase III trials demonstrated oxaliplatin’s effectiveness in this setting, there were few further developments in adjuvant therapy for...